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Tumor  Necrosis Factor/cachectin (TNF) 1 has been implicated as a  mediator 
of the host response in sepsis and neoplasia (1-2). The close relationship between 
the  septic state and  coagulation abnormalities  (e.g.,  disseminated  intravascular 
coagulation), and the hemorrhagic nature of the lesions in the tumor bed induced 
by TNF  (2) suggest  that defects in  the hemostatic system may result from the 
action  of TNF.  In  this  context,  recent  studies  have  indicated  that  TNF  can 
modulate hemostatic properties of the cells forming the luminal vascular surface, 
the  endothelium  (3).  Through  the  concomitant  induction  of endothelial  cell 
procoagulant activity and suppression of anticoagulant mechanisms, TNF renders 
the vessel wall a potentially effective surface for thrombotic phenomena and the 
ensuing coagulopathies. These data suggest the hypothesis that endothelium is a 
target tissue for TNF. 
To  serve  as  a  target  tissue  for  an  inflammatory  mediator  such  as  TNF, 
endothelium would be expected to provide both binding sites and an amplifica- 
tion  mechanism  through  which  the  TNF-stimulated  cell  could  augment  the 
inflammatory response. This would be analogous to the chain of events set into 
motion by IL-1 acting on the lymphocyte to promote IL-2 generation, and thus 
lymphocyte proliferation  potentiating  the  immune  response  (4).  In  this  study 
cultured human  umbilical  vein endothelial cells are shown to possess saturable 
and  high  affinity binding  sites  for  TNF.  Furthermore,  specific interaction  of 
TNF  with  endothelium  leads  to the  synthesis and  release of IL-1.  These data 
indicate that  TNF  can  initiate a  cascade of inflammatory events on  the  vessel 
surface both directly and  through the stimulation  of endothelial  cell IL-1  gen- 
eration. 
Materials and Methods 
Cell Culture.  Endothelial cells derived from human umbilical cord veins were prepared 
by the method ofJaffe et al.  (5 and 6), as modified by Thornton et al. (7). Endothelial 
cells  were  harvested  from  umbilical  veins,  cells  were  placed  in  tissue  culture  flasks 
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pretreated  with  gelatin  (0.25%;  gelatin  solutions contained  1 #g/ml polymyxin B) and 
growl1  ill  medium  199 (Gibco Laboratories, Grand  Island, NY) containing  heparin  (90 
ug/ml; Sigma Chemical  Co.,  St.  Louis,  MO), endothelial  cell  growth  factor (20 #g/ml; 
Meloy Laboratories, Springfield, VA), human serum (20%; prepared from normal human 
vohmteers), and pencillin-streptomycin (50  U/ml-50 ug/ml; Gibco Laboratories). After 
confluence was achieved (0.7-1.1  x  105 cells/cmZ),  cells were subcultured using trypsin- 
EI)TA (0.25-0.05%; Gibco Laboratories). Cultures were characterized as endothelial cells 
based on  morphologic criteria  (5)  and  by positive immunofluorescence staining with  a 
specific anti-Factor VIll/von  Willebrand  factor antibody (generously provided by Drs. 
Chnpek and Davie, University of Washington, Seattle, WA) (8). By passage 1, endothelial 
cell cultures contained no monocyte/macrophage cells, as judged by morphologic criteria 
and  by cytofluorometry  using  OKM2,  an  mAb  reactive  with  the  majority of human 
monocytes/macrophages (9).  Absence of T  lymphocytes from cultures was also assessed 
cytofluorometrically using the monoclonal antibody OKT3  (10).  A[t experiments were 
carried out 24 h after endothelial ceils achieved confluence in 9.6-cm  z dishes except for 
the rebinding studies (Fig.  3) which employed 75 cm  ~ tissue culture flasks. 
Reagents and Assays.  Recombinant human TNF, generously provided by BASF (Lud- 
wigshafen, Federal Republic of Germany), was used for all studies. This TNF preparation, 
which was free of detectable endotoxin at the concentrations employed in these studies, 
migrated  as  a  single  band  with  an  apparent  molecular weight  of  17,500  under  both 
reducing and nonreducing conditions on SDS-PAGE (11). This material was distinct from 
lymphotoxin, had no activity in an IL-1 thymocyte costimulation assay, and had a specific 
activity of ~ 10  s U/rag using a TNF cytolytic assay (12). The amino acid composition and 
N-terminal sequence corresponded to that previously reported (13;  14; and Kirchner et 
al., manuscript in preparation).  Heat-treatment of TNF was carried out at 70°C for 1 h 
and resulted in loss of cytolytic activity (15). 
Radiolabeling  of TNF  was accomplished  using  1,3,4,-G-tetrachloro-3c~,  6~-diphenyl 
glycoluril (Iodogen; Pierce Chemical Co. Rockville, MD) (16).  Free iodine was separated 
from  TNF  by gel  filtration  using  a  column  (20  cm) of Sephadex  G-25.  The  specific 
radioactivity of 125I-TNF was 25-40,000  cpm/ng over four radioiodinations.  Radioiodi- 
nated TNF migrated as a single band on reduced (Fig.  2) or nonreduced SDS-PAGE and 
comigrated with the unlabeled material. After the radiolabelling procedure, TNF retained 
70-90% of its original activity as determined by a cytotoxic assay on L929 cells (12). 
Monospecific rabbit antiserum to human TNF was provided by BASF. The IgG fraction 
of rabbit antiserum to human IL-1 was purchased from Genzyme (Boston, MA). Control 
serum was obtained from rabbits not specifically immunized with any protein. The IgG 
fractions  of antisera  were  prepared  using  staphylococcal protein  A-Sepharose  CL-4B 
(Pharmacia Fine Chemicals,  Piscataway, NJ) by the  method of Goding (17).  IgGs were 
immobilized on affigel 10 (~2 mg of protein per ml of resin) following the manufacturer's 
protocol.  Columns  were  then  equilibrated  and  run  in  serum-free  medium  (minimal 
essential medium containing penicillin-streptomycin [50  U/ml-50 ug/ml],  1 ug/ml poly- 
myxin B, 10 mM Hepes [pH 7.4], 20 ug/ml transferrin, and 10 #g/ml insulin and 5 mg/ml 
BSA). 
Electrophoresis was carried out by the method of Laemmli (11) employing 12.5% gels. 
For autoradiography,  gels  were  dried  and  exposed to  X-Omat (XAR5)  film (Eastman 
Kodak Co., Rochester, NY) in the presence of a Cronex intensifying screen (Dupont Co., 
Wilmington, DE). Standard proteins, including lysozyme (14,400), soybean trypsin inhib- 
itor (21,500),  carbonic anhydrase (31,000),  OVA (45,000),  BSA (66,200) and phospho- 
rylase B (92,500) (Bio-Rad Laboratories, Cambridge, MA.) were run simultaneously. 
IL-I activity was  measured  in  a  costimulation assay using  murine  thymocytes as de- 
scribed previously (18).  Thymocytes (1.5  X  106/well)  from 4-8-wk-old C3H/HEJ mice 
(The Jackson Laboratory, Bar Harbor, ME) were cultured for 72 h in Iscove's modified 
I)ulbecco's medium (Gibco Laboratories) containing  FCS (10%),  glutamine (1%),  [3-ME 
(50 uM),  and  PHA  1%.  Endothelial cell supernatants (50 #1) were added to wells at the 
starl of a 72 h assay, and [~H]thymidine (1 #Ci/well; New England Nuclear, Boston, MA) 
was  added  18  h  before  harvesting.  Before  assaying  supernatants  of endothelial  cells NAWROTH  ET  AL.  1365 
containing  added  cycloheximide,  samples  were  extensively  dialyzed  vs.  saline  (dialysis 
tubing had a molecular weight cutoffof 3,500). Control samples containing cycloheximide 
and medium not exposed to cells were also dialyzed and assayed. Under these conditions 
cycloheximide  had  no  effect  on  thymocyte  proliferation  in  response  to  added  IL-1 
(Genzyme). In addition to studying culture supernatants, a lysate of endothelial cells was 
also  assayed.  The  lysate  was  prepared  by three  freeze-thaw cycles (-80  to  37°C)  and 
cellular debris was removed by centrifugation (10,000g for 20 rain). Samples were assayed 
in triplicate.  TNF,  up to  100  nM,  did  not  induce thymocyte proliferation  above back- 
ground in this assay. 
TNF Binding Assays.  Binding studies were carried out at 4 °C after washing endothelial 
cells twice with calcium- and magnesium-free HBSS.  1 ml serum-free medium (Medium 
199 containing penicillin-streptomycin  [50 U/ml-50 tsg/ml],  10 mM Hepes [pH 7.4],  20 
ug/ml transferrin,  10 ug/ml insulin, 1 ug/ml polymyxin B, 5 mg/ml human serum albumin) 
containing  radiolabeled  TNF  alone  or  radiolabeled  TNF  in  the  presence  of excess 
unlabeled TNF was then added for the indicated times. The concentration of unlabeled 
TNF  used  to  displace  specific  binding  in  these  studies  was  a  300-fold  molar  excess 
compared with  ~'~'~I-TNF. Addition of more unlabeled material had no effect on specific 
binding. Binding was terminated by five rapid washes (1 ml/wash) with serum-free medium 
(4°C).  Cells were solubilized with tris (50 raM; pH 7.4)-saline (0.1  M) containing NP-40 
(1%).  No binding  was observed  in  wells  without  cells.  Data  from binding  experiments 
were fit to the equilibrium binding equation: [B -- nK +  (1  +  KA)] (19), assuming a one- 
site model, where B is the amount bound, n is the number of sites per cell, A  is the free 
concentration of radioligand, and K is the association constant. A nonlinear, least-squares 
program (SAS Institute,  Cary,  NC) was used to obtain  the best fit curve, to solve for n 
and  K,  and  to  determine  the  standard  error.  A  plot  of residuals  vs.  free  radioligand 
concentration  for the  binding  data  shown  in  Fig.  4  indicated  no systematic error  was 
involved in fitting the binding to the model used (data not shown). 
Dissociation studies were carried out using the method of infinite dilution (Fig.  1 B) as 
described by Lollar et al.  (20); after cell monolayers were incubated with  ~5I-TNF and 
washed  free of unbound  protein,  fresh,  serum-free  medium  was added  (1  ml).  At  the 
indicated times, incubation buffer was asperated, the dishes were washed twice (1 ml/wash) 
with  the same buffer, and  soJubilized as described above.  Dissociation of 12SI-TNF  was 
also studied in the presence of excess unlabeled TNF and by incubating monolayers with 
glycine (50 mM; pH 3.0)-saline (0.1  M)-EDTA (5 raM) (21) for 2 min at 4°C. The latter 
treatment did not result in loss of endothelial cell viability or detachment from the culture 
dish (see Results). 
The ability of I~5I-TNF to rebind to endothelial cell monolayers after elution from cells 
was  tested  as  follows  (Fig.  3):  ~251-TNF  (300  pM)  was  incubated  with  endothelial  cell 
monolayers in  75-cm ~ tissue  culture  flasks  (five  flasks  in  total)  for  2  h  at  4°C.  After 
washing to remove  unbound material,  cell-bound  v'SI-TNF was eluted  with  glycine (50 
raM; pH 3.0)-saline (0.1  M; 3 ml/flask) as described above. Eluted  IzSI-TNF was immedi- 
ately restored  to pH 7.4 by the addition  of 2  M  tris (pH  8.0), dialyzed vs.  protein-free, 
serum-free medium (4 °C), concentrated by exposure to Sephadex G-10 (Pharmacia Fine 
Chemicals) while still  within  the dialysis bag, and further dialyzed vs.  the same medium. 
Finally, eluted  ~I-TNF  was diluted with serum-free medium to a final ~5I-TNF concen- 
tration of 45 pM. The endothelial  cell binding of ~I-TNF  eluted from the cell surface 
was then compared with the binding of v~I-TNF not previously exposed to cells (Fig. 3). 
Colloidal Gold Labeling  and Electron Microscopy.  Suspensions  of colloidal  gold  were 
prepared  (22)  with  an  average  diameter  of  15.6  4-  1.1  nm  (mean  4-  S.D.)  and  at  a 
concentration  of 1.9  x  10 ~" particles/ml  (23).  Optimal  adsorption  of TNF to colloidal 
gold occurred when the pH of the reaction mixture was adjusted to the pI of TNF (13). 
The completeness of TNF adsorption to the gold particles was determined using the serial 
dilution-electrolyte flocculation test (24-25).  After labeling, TNF-gold suspensions were 
adjusted  to  isotonicity  with  sucrose and  albumin.  Colloidal  gold  was also  labeled  with 
albumin to assess nonspecific binding in the cell labeling studies.  Experiments were then 
carried out as described for radioligands.  Nonspecific binding of TNF-gold probes to the 1366  TUMOR  NECROSIS  FACTOR-INDUCED  RELEASE  OF  INTERLEUK1N  1 
cell  surface was  determined in  the presence of one hundredfold molar excess of free 
TNF. Nonspecific colloid binding was evaluated using human serum albumin, colloidal 
gold conjugates. The surface density of TNF-gold probes on endothelial cells was deter- 
mined from thin sections of each culture plate (26).  A total of 25 electron micrographs 
was photographed from thin sections of each sample. 
For transmission electron microscopy, monolayers were fixed in a glutaraldehyde (1%) 
and acrolein (0.5%) in sodium cacodylate (0.1  M, pH 7.35,475 mosmol) for 30 rain. Cells 
were postfixed for one hour in osmium tetroxide (1%), stained with uranyl acetate (2%), 
dehydrated in an ascending ethanol series,  and embedded in  Spurr's resin (27).  Thin 
sections  (50  nm)  were  contrasted  with  lead  citrate  and  viewed  in  a  EM-95  electron 
microscope (Carl Zeiss, Inc., Thornwood, NY). 
Treatment of Endothelial Cells with Unlabeled TNF.  Confluent endothelial cell monolay- 
ers (9.6-cm  2 dishes) were washed twice with  calcium- and magnesium-free HBSS, then 
serum-free medium (1  ml) was added in the presence of other proteins as indicated, and 
cultures were incubated at 37°C.  In experiments using cycloheximide (1  •g/ml;  Sigma 
Chemical Co.), this inhibitor was added simultaneously with the TNF. Throughout these 
experiments, endothelial cell viability was >95%, as assessed  by trypan blue exclusion and 
morphologic criteria. 
Results 
Previous studies have shown that incubation of confluent, cultured endothelial 
cells  with  TNF  is  not  lethal  for the  cells  and  leads  to  the  modulation  of cell 
surface coagulant properties (3). These data suggested that endothelium would 
possess specific interaction sites for TNF. When cultured human umbilical vein 
endothelial  cells  were  incubated  with  recombinant  human  ~25I-TNF,  time-de- 
pendent binding was observed (Fig.  1 A). At 4°C, binding reached an apparent 
maximum  by 80  min  even at  the  lowest concentrations of 125I-TNF used  (30 
pM). The second order rate constant for association, calculated from the data in 
Fig.  1A was ~4.1  X  10 7  M -l  min -l.  The concentration of binding sites used in 
this calculation was taken from the data in Fig. 4. At 37°C, cellular association 
was  more rapid,  but surface binding was  followed by cellular processing.  This 
was indicated by the incomplete elution of cell-associated 125I-TNF during a brief 
exposure to trypsin (2 mg/ml for 5 rain at 21 °C), when binding was carried out 
at 3 7 ° C, compared with complete elution when binding was carried out at 4 ° C. 
These results, which suggest that cell-associated ~25I-TNF is not confined to the 
cell  surface at  the  higher  temperature,  are  consistent  with  endocytosis of the 
ligand.  Endocytosis of surface bound TNF has been reported by Baglioni et al. 
(21) during studies of the interaction of TNF with HeLa cells. Thus, in order to 
define equilibrium-binding parameters  in  the present  study, experiments were 
carried out at 4 ° C. 
Dissociation  studies  (Fig.  1B)  indicated  that  interaction  of  125I-TNF  with 
endothelium was reversible with a first-order dissociation constant of 5.1  x  10 -3 
min -~.  A  similar  dissociation  rate  was  observed whether  elution  of cell-bound 
TNF was studied by the method of infinite dilution or in the presence of excess 
unlabeled TNF. Although several hours were required for complete dissociation, 
TNF was on the cell surface, since a  2 min exposure at 4°C to glycine (50 mM, 
pH  3.0)-saline  (0.1  M)-EDTA (5  mM)  buffer (21)  resulted  in  rapid  elution  of 
cell-associated  125I-TNF  (Fig.  1B),  but  did  not  disrupt  the  intact  monolayer. 
Elution  of cell-bound TNF  was also  complete in  the  presence of NP-40  (1%). 
SDS-PAGE  of the  detergent  eluates  indicated  that  the  initial  tracer  and  cell- NAWROTH  ET  AL.  1367 
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FIGURE  1.  Time course and reversibility of zzSI-TNF binding to endothelial  cells. (A) Time 
Course: Endothelial  cell monolayers (passage 2) were incubated for the indicated  times with 
125  125  1-TNF (150 pM) alone or  I-TNF in the presence of excess unlabeled TNF (45 nM). Total 
bindin~ (©), binding observed with ]25I-TNF alone; nonspecific binding (x), binding observed 
with  ]~ I-TNF in  the presence of unlabeled  TNF; and specific binding (e),  the difference 
between  total  and nonspecific  binding.  The mean of duplicates  is shown.  (B) Reversibility: 
Endothelial cell monolayers (passage 1) were incubated with ]eSI-TNF (180 pM) for 2 h at 4°C 
and then washed four times as described  in Materials and Methods.  At this point (time 0), 
fresh,  serum-free medium (1.0 ml) (O), or glycine (50 raM; pH 3.0)-saline (0.1 M)-EDTA (5 
mM) buffer (1 ml) (e) was added. The dishes were then incubated at 4°C for the indicated 
times, washed, and solubilized.  Nonspecific  binding was determined from a set of dishes in 
which 125I-TNF (180 pM) and unlabeled  TNF (50 nM) were added simultaneously.  Maximal 
specific binding (time  0) was  1.6 fmol/well.  The  mean and  SEM  of the percent maximal 
specific binding is plotted vs. time. 
bound material migrated identically with Mr ~ 17,500 (data not shown). Although 
the  molecular  weight  of cell-bound  125I-TNF  on  SDS-PAGE  appeared  to  be 
unchanged,  since  only  a  small  portion  (1-11%)  of the  total  added  ]25I-TNF 
became  cell-associated  it  was  important  to  determine  whether  cell-bound  ]25I- 
TNF  was  representative  of the  total  pool  of radiolabelled  material,  i.e.  not  a 
subpopulation of damaged molecules. To test this cell-bound ]25I-TNF was eluted 
from monolayers, dialyzed, and reapplied to fresh cultures. Simultaneously, fresh 
125I-TNF  was  diluted  to  the  same  concentration  and  incubated  with  other 
endothelial  cell  monolayers.  In  each  case  a  comparable  amount  of  ]25I-TNF 
bound  to the  endothelium.  Thus,  cell-bound  I~SI-TNF is  representative  of the 
total pool of ]z5I-TNF. 
Employing  these  conditions  for equilibrium  binding,  the  association  of 125I- 
TNF  with endothelium  was observed to be saturable  (Fig.  2).  Binding was half- 
maximal at  105 +  40 pM and, at saturation  there were  1.5 +  0.5 ×  103 sites/cell. 
Experiments  in  which  1251-TNF was diluted  with  unlabeled  TNF  showed  com- 
parable  binding  parameters,  indicating  that  unlabeled  and  labeled  TNF  inter- 
acted  with  endothelium  similarly.  In  contrast,  heat-treated  TNF,  which  lacks 
biologic activity (3,  15), does not bind to endothelial  cell monolayers (Fig.  2). 1368  TUMOR  NECROSIS  FACTOR-INDUCED  RELEASE  OF  INTERLEUKIN  1 
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FIGURE  2.  Saturability  of  ~:'I-TNF  binding  to  endothelial  cell  monolayers  (passage  1). 
Endothelial cell monolayers were incubated for 2 h at 4°C with the indicated concentrations 
of ~'I-TNF alone (total binding or  ~2'I-TNF in the presence of a  300-fold molar excess of 
unlabeled TNF.  The binding assay was carried out as described  in Materials and Methods. 
Specific binding (total minus nonspecific binding) is plotted vs.  free ~2~I-TNF (O). Data were 
analyzed by the nonlinear least squares program and the curve (-) indicates the best fit line. 
Nonspecific binding accounted for 15-23% of the total binding. Where indicated, heat-treated 
~z~I-TNF and unlabeled TNF were used (0). 
FIGURE  3.  Binding of TNF-colloidal gold particles to endothelial cell monolayers. Endothe- 
lial  cell  monolayers  (passage  2)  were  incubated  for  2  h  at  4°C  with  TNF-gold  probes 
(corresponding to a TNF concentration of 177 pM and 1.9 ×  101"~  probes/ml). After washing 
(4°C) to remove unbound material, samples were immediately processed for electron micros- 
copy (see in Materials and Methods). TNF-gold particles are randomly distributed at the outer 
membrane surface. Bar, 0.1  #m. NAWROTH  ET  AL.  1369 
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FIGURE 4.  Elaboration  of IL-1 activity by TNF-treated endothelial  cells. (A) Endothelial cell 
monolayers (passage 4) were incubated in serum-free  medium in the presence  or absence of 
TNF (250 pM) for 18 h at 37°C. Samples from TNF-treated cells were diluted in serum-free 
medium,  as  indicated,  and assayed  for IL-1  activity  in  the  thymocyte proliferation  assay. 
Samples from untreated cells (©) were assayed at a 1:2 dilution; identical results were observed 
at 1:1 and 1:4 dilutions.  Sample dilution  is plotted vs. [3H]thymidine incorporation. (B) Effect 
of anti-IL-1  affigel  10  on  the  IL-1  activity  of TNF-treated  endothelial  cell supernatants. 
Endothelial  cell monolayers (passage 3) were incubated in serum-free  medium for 17 h at 
37°C. Aliquots of cultured supernatants (0.3 ml) were then chromatographed on an anti-IL- 
l column (bed volume, 0.5 ml) or a column made by coupling nonimmune rabbit IgG to the 
resin (bed volume, 0.5 ml). The initial culture supernatant (a), the pass-through  fraction from 
the anti-IL-1 column (b), and the pass through fraction from the control IgG column (c) were 
assayed in the thymocyte proliferation assay. The mean _+ 1 SD of triplicate determinations  is 
shown in both A and B. 
To complement the radioligand binding studies and establish that bound TNF 
was associated  with the endothelial  cell surface, morphologic studies  using gold- 
labeled TNF  were carried out (Fig. 3). Gold-labeled TNF  bound to endothelium 
over a similar range of concentrations and incubation times as that of radiolabeled 
TNF.  The  presence of a  three  hundredfold  molar excess of TNF  not bound to 
gold blocked endothelial cell binding of TNF  colloidal gold conjugates by >85%. 
At 4°C,  TNF-gold  particles  were distributed  in a  random  manner,  but  closely 
opposed  to  the  luminal  cell  surface.  The  binding  of BSA-gold conjugates  was 
<5% of that observed with TNF-gold conjugates.  These data indicate that TNF 
does interact with sites on the endothelial  cell surface. 
To more fully understand  the pathophysiologic implications of the interaction 
of endothelium  with  TNF,  generation  of IL-t  (28) by TNF-treated  endothelial 
cell  monolayers  was  studied.  When  TNF  was incubated  with  confluent  human 
endothelial cells, release of IL-1 activity occurred (Fig. 4A). Using the thymocyte 
costimulation  assay  (18),  I L-1  activity  was  clearly  detectable  in  serially  diluted 
supernatants  of TNF-treated  endothelial  cells.  Adsorption  of IL-1  activity  in 
culture  supernatants  by an  antibody  to  IL-1  coupled  to  a  solid-phase  support 1370  TUMOR  NECROSIS  FACTOR-INDUCED  RELEASE  OF  INTERLEUKIN  1 
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F[(3ueE  5.  Time  course  of TNF-induced elaboration of IL-I  activity by endothelial cells. 
Endothelial cell monolayers (passage 2) were incubated in the presence of either TNF (200 
pM) (0), or heat-treated  TNF (220 pM) (x), or in serum-free medium alone (O) for the 
indicated time at 37°C. The supernatants were then assayed for IL-1 activity in the thymocyte 
proliferation assay as described. The mean + 1 SD of triplicate determinations is shown. 
(Fig.  4B)  suggests  that  IL-l-like  molecules  were  responsible  for the  observed 
proliferative response.  A  control column with nonimmune  IgG coupled to the 
resin had no effect on IL-1 activity in culture supernatants. 
Since lipopolysaccharide has  been  shown  to cause  release of endothelial  cell 
IL-1  (28),  it was  important to determine whether TNF  in the preparation  was 
responsible for the elaboration of IL-1  activity. In this context, following chro- 
matography of a stock TNF solution (5 nM) over an affigel 10 column (0.6 ×  20 
cm)  with  immobilized  rabbit  antiserum  to  TNF,  pass-through  fractions  were 
ineffective  in  the  induction  of endothelial  cell  IL-1.  A  control  column  with 
nonimmune IgG coupled to the resin did not diminish the potency of the TNF 
preparation for the induction of endothelial cell IL-1.  Furthermore, heat treat- 
ment of the TNF preparation destroyed its efficacy for IL-1 generation (Figs. 5, 
6), although there was no effect on 1L-1  release initiated by exogenous lipopol- 
ysaccharide (data not shown). Thus, TNF was responsible for the observed IL-1 
generation in these experiments. 
Induction  of IL-1  by  TNF  occurred  in  a  time-dependent  manner  (Fig.  5). 
Increased IL-1 activity was detectable in culture supernatants by 6 h and reached 
a  maximum  b ,r 24  h.  Addition of cycloheximide (1  t~g/ml) blocked elaboration 
of IL-1 activity (Fig.  7), suggesting that de novo protein synthesis was required 
for endothelium to generate IL-1. Further data to support this view are provided 
by experiments indicating that endothelial cell lysates did not contain significant 
amounts  of IL-1  before  TNF-treatment  (data  not  shown  and  reference  28). 
These  results  are  similar  to  lipopolysaccharide-induced  endothelial  cell  IL-1 
generation, where protein synthesis was also required (28). 
Generation of IL-1  by endothelium was also dependent on the concentration 
of TNF  incubated with  the cultures (Fig.  6).  IL-1  generation was half-maximal 
at a TNF concentration of 40-80 pM and reached a maximum by 300 pM. The 
general  correspondence between  parameters  of TNF  induction  of endothelial 
cell  IL-1  and  ~25I-TNF  binding  to  the  monolayers suggests  that  it  is  the  cell- NAWROTH  ET  AL.  1371 
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FIGURE 6.  The effect of TNF-concentration on the generation of IL-1 by endothelial cells. 
Endothelial cell monolayers (passage 2) were incubated for 18 h at 37 °C in serum-free medium 
in the presence of either the indicated concentration of TNF  (O) or heat-treated TNF (<9). 
Samples were then assayed in the thymocyte proliferation assay. The direct effect of TNF (0.8 
nM) added to the thymocyte assay in the absence of endothelial cell supernatant is shown (a). 
The mean 4- 1 SD of triplicated determinations is shown. 
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FIGURE  7.  Effect  of  cycloheximide  on  TNF-induced  IL-1  elaboration.  Endothelial  cells 
(passage 1) were incubated either with TNF (25 pM) (A), TNF (25 pM) and cycloheximide (1 
/~g/ml) (B),  or serum-free medium  alone (C).  This concentration of cycloheximide did not 
reduce cell viability. Culture supernatants were dialyzed extensively vs. saline, and assayed for 
IL-1  as described in  Materials and  Methods.  1 #g/ml cycloheximide, after dialysis,  had no 
effect on the thymocyte proliferation assay. The mean 4- 1 SD. is shown. 
bound TNF that stimulates IL-1 generation. This hypothesis is supported by the 
observation that heat-treated TNF neither binds to endothelium nor induces IL- 
l  generation even at levels as high as 300 pM (Fig. 6). 
Discussion 
The results reported here indicate that cultured endothelium provides a target 
for the  monokine TNF.  In contrast to its lethal effect on certain transformed 
tumor cell lines (2), TNF is not toxic to confluent cultured human endothelium 
(3).  Rather, it binds to the cell surface in a  saturable, high affinity manner and 
promotes  IL-1  generation.  Consistent  with  these  results,  the  febrile  response 
observed in patients and mice infused with TNF may involve TNF-induced IL- 
l  release (2,  29).  This suggests that the pathophysiology of disorders in which 
TNF plays an  integral  role involves not only direct action of TNF  on cellular 
targets,  but  also  an  amplification  mechanism  involving  IL-1  and  its  cellular 
targets.  For  example,  within  2  h  of exposure  to  TNF,  before  the  release  of 1372  TUMOR NECROSIS FACTOR-INDUCED RELEASE OF  INTERLEUKIN 1 
detectable  amounts of IL-1,  endothelial  cells  undergo a  modulation of their 
coagulant properties  allowing  them  to  promote  activation  of the  hemostatic 
mechanism (3). Subsequently, IL-1  is generated, both in response to TNF and 
thrombin formed by the activated coagulation system (28), and can interact with 
other vascular beds, resulting in the induction of procoagulant activity in their 
endothelium. This series of events could well underlie the diffuse coagulopathy 
associated with the septic state or the prothrombotic diathesis observed in patients 
with malignancies. 
An alternative possibility suggested by the data presented  here is  that IL-1 
mediates certain  changes  in  endothelial cell  physiology initiated by  TNF.  In 
support  of this  hypothesis,  both  TNF  and  IL-1  result  in  the  induction  of 
endothelial cell  tissue  factor  (3,  30,  31).  To  test  this,  endothelial  cells  were 
incubated with TNF (50 pM) in the presence of anti-IL-1 IgG at a concentration 
that inhibits thymocyte proliferation (18)  in response to 50 U/ml of IL-1. The 
latter concentration of I L-1 is considerably more than that detected in endothelial 
cell supernatants after treatment of monolayers with TNF. The antibody to IL- 
l  had  no effect on  tissue factor induction compared with nonimmune IgG or 
medium  alone.  In  contrast,  this  antibody  blocked  tissue  factor  induction  in 
response to purified exogenous IL-1 (10 U/ml). In this context, when endothelial 
cells  were incubated simultaneously with TNF and IL-1  more tissue factor was 
observed than with either agent alone. These results suggest that TNF and IL-1 
may act  independently to bring about  the  induction of endothelial cell  tissue 
factor. However, these results must be interpreted with caution since the possi- 
bility remains that IL-1 produced in response to TNF acts at a location inacces- 
sible to the IL-1 antibody. 
The  close  relationship  between  the  concentrations of TNF  that  modulate 
endothelial cell hemostatic properties (half-maximal at 40-70 pM) observed in a 
previous  study (3),  and  levels that  induce endothelial cell  IL-1  and  result  in 
occupancy of TNF  cell  surface binding sites suggests that  these  sites may be 
involved in mediating the effect of TNF on the vessel  surface. Recent data of 
Rubin et al.  (32),  indicating that mouse L(M) cells sensitive to TNF bound the 
monokine specifically, but resistant L(M) cells did not, support the concept of a 
relationship between the presence of TNF binding sites and a cellular response 
to TNF. The affinity of 125I-TNF for the endothelial cell surface (105 +  40 pM) 
is similar to  the affinity of radiolabeled TNF  for other cellular surfaces with 
specific binding sites  (100-300  pM) (21,  32-33).  The number of binding sites 
on  the  endothelial cell  surface  (~1,500  sites/cell)  is  somewhat  less  than  that 
reported in two studies (21,  33).  In contrast, Baglioni et al. (21) and Beutler et 
al. (33)  found ~6,000 and -10,000 TNF-binding sites/cell, respectively, on cell 
populations sensitive to TNF. Furthermore Baglioni et al. (21)  noted decreased 
sensitivity of cells  to  TNF  with  fewer  TNF-binding  sites.  This  suggests  the 
hypothesis that TNF could become toxic to endothelium or more effective in 
IL-1  induction if the  number  of endothelial cell  TNF  sites  was  increased  in 
pathologic states. For example, the in vivo tumoricidal effect of TNF could be 
related to concentration of TNF in the tumor vascular bed by endothelium with 
increased numbers of TNF receptors. 
The demonstration of TNF binding sites on endothelium coupled with TNF- NAWROTH  ET  AL.  1373 
induced IL-1 generation and modulation of endothelial cell hemostatic properties 
contributes  to  an  emerging  picture  in  which  the  vessel  surface  could  play  a 
central role in the pathophysiology of TNF-mediated disorders. The interaction 
of TNF with endothelium may thus contribute to the pathogenesis of the diffuse 
coagulopathy associated  with  sepsis  and  the  apparent  "collapse of vasculature 
around tumors" noted by investigators who examined destruction of tumors in 
vivo by endotoxin 30 years ago (34-36). 
Summary 
Tumor necrosis factor/cachectin (TNF) has been implicated as a  mediator of 
the host response in sepsis and neoplasia. Recent work has shown that TNF can 
modulate endothelial cell hemostatic properties, suggesting that endothelium is 
a  target tissue for TNF. This led us to examine whether endothelial cells have 
specific binding sites for TNF and augment the biological response to TNF by 
elaborating  the  inflammatory  mediator,  IL-1.  Incubation  of  r~SI-recombinant 
human  TNF  with  confluent,  cultured  human  umbilical  vein  endothelial  cells 
resulted in time-dependent, reversible, and saturable binding.  Binding was half- 
maximal  at  a  TNF  concentration  of  105  _+  40  pM,  and  at  saturation  1,500 
molecules were bound per cell. Heat-treated TNF, which is biologically inactive, 
did not bind to endothelium.  In addition to surface binding,  TNF induced the 
elaboration  of IL-1  activity  by  endothelial  cells  in  a  time-dependent  manner. 
Generation of IL-1 activity required protein synthesis and was half-maximal at a 
TNF concentration of 50 _+ 20 pM. IL-1 activity from TNF-treated endothelium 
could be adsorbed by an immobilized antibody to IL-1.  Heat-treated TNF was 
ineffective in eliciting endothelial cell IL-1. These data indicate that TNF  can 
bind  specifically  to  endothelium  and  initiate  a  cascade  of inflammatory  and 
coagulant events on the vessel surface potentially central to the host response to 
neoplasia and sepsis. 
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